Molecular testing in NSCLC stage IV: why are not 100% of patients tested?
A Lüers, N Neemann, M Hoheisel, K Wedeken, R Prenzel, DC Scriba, K Willborn, U Stropiep, M Tiemann, F Griesinger · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Introduction: The current guideline for NSCLC recommends testing for molecular alterations in all non-squamous cell carcinoma patients stage IV and in squamous cell carcinoma patients if they are never or light smokers (< 10 packyears, > 15 years smoking cessation). However, most patients are diagnosed in an in-patient setting for which testing is not yet reimbursed. Therefore, the intention of this study was to analyze the number of patients and the reasons for not testing in our lung cancer center which has access to the out-patient setting. Methods: All primary NSCLC cases stage IV in the lung cancer center w…
